Idogen (IDOGEN.ST) Stock Analysis & AI Equity Report
Idogen (IDOGEN.ST) overview
Idogen (IDOGEN.ST) stock analysis and AI equity research. For the latest completed financial year, 2022, Idogen reported revenue of SEK 0m and operating profit of SEK -48.0m; the year-end share price was 0.18 SEK and market capitalisation was SEK 11.0m. Idogen is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Idogen's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Idogen
Idogen AB is a Swedish biotechnology company developing tolerogenic cell therapies intended to re-establish immune tolerance. Its programs are aimed at preventing the immune system from attacking biological treatments, transplanted organs, or the body’s own tissues, with lead work in hemophilia patients who have developed neutralizing antibodies and broader applications in transplantation and autoimmune disease.
Generate the Idogen report
Idogen is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Idogen and represent the latest completed financial year (2022). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.